v3.26.1
Related Parties Transactions (Tables)
 12 Months Ended
Dec. 31, 2025
Related party transactions [abstract]  
Schedule of Key Management Personnel Compensation The key management personnel compensation of the Group was as
follows for the years ended December 31:
2025
$
2024
$
2023
$
For the years ended December 31,
Short-term employee benefits
3,918
5,166
9,714
Post-employment benefits
76
61
41
Termination benefits
408
395
417
Share-based payment expense
2,174
2,540
599
Total
6,576
8,161
10,772
Schedule of Directors’ and Senior Managers’ Shareholdings and Share Incentive Awards The Directors and senior managers hold beneficial interests in shares in the following businesses as of December 31, 2025:
Business name (share class)
Number of
shares held as
of December
31, 2025
Number of
options held as
of December 31,
2025
Number of
RSUs held as of
December 31,
2025
Ownership
interest¹
Directors:
Dr Robert Langer
Entrega (Common)
250,000
82,500
—
4.35%
Dr John LaMattina
Vedanta Biosciences (Common)
2,500
427,416
—
0.15%
Seaport Therapeutics (Preferred B)2
21,052
—
—
0.01%
Michele Holcomb
Seaport Therapeutics (Preferred B)
21,052
—
—
0.01%
Sharon Barber-Lui
Seaport Therapeutics (Preferred B)
21,052
—
—
0.01%
Kiran Mazumdar-Shaw
Seaport Therapeutics (Preferred B)3
21,052
—
—
0.01%
Senior Managers:
Eric Elenko
Seaport Therapeutics (Common)
950,000
—
—
0.63%
1Ownership interests as of December 31, 2025 are calculated on a diluted basis, including issued and outstanding shares, warrants and options (and written commitments to issue
options) but excluding unallocated shares authorized to be issued pursuant to equity incentive plans.
2Dr. John and Ms. Mary LaMattina hold 21,052 Series B preferred shares of Seaport Therapeutics.
3      Shares owned through Glentec International.